A -- BROAD AGENCY ANNOUNCEMENT FOR BIOMEDICAL RESEARCH 2001

Notice Date

May 18, 2001

Contracting Office

United States Special Operations Command, Directorate of Procurement (SOAL-KB), 2418 Florida Keys Ave., MacDill AFB, FL 33621-5316

ZIP Code

33621-5316

Response Due

April 30, 2003

Point of Contact

Mr. John Thompson, 813-828-7077

E-Mail Address

For more information, contact Mr. Thompson via email. (thompsj@socom.mil)

Description

1. The US Special Operations Command is soliciting pre-proposals directed at basic and applied biomedical research focusing on Special Operations Forces (SOF)-relevant aspects of medical care, particularly related to: combat casualty management; medical aspects of mission planning, biomedical training, environmental protection, vibration/shock injury, nutrition, hydration, diving procedures equipment and injuries, exercise and mission related physiology, field diagnostic and care equipment; and medical information management systems. This notice constitutes a Broad Agency Announcement (BAA) as contemplated in FAR6.102(d)(2). 2. The following general aspects/topic areas of basic and applied biomedical research are of interest: 2.1 Casualty Management 2.1.1 Hespan/crystalloid comparative study in delayed surgery (animal studies). 2.1.2 Hypotensive resuscitation study (human studies). 2.1.3 Card diagnostics in SOF. 2.2 Medical Aspects of Mission Planning 2.2.1 Medical aspects of Foreign Internal Defense missions. 2.3 Biomedical Training 2.3.1 SOF corpsman/medic skills utilization studies. 2.3.2 Medical simulations in SOF medical training. 2.4 Thermal Protection 2.4.1 Thermal protection in dive/overland transition operations. 2.4.2 Cold acclimatization schedules. 2.5 Nutrition/Hydration 2.5.1 Carbohydrate loading and SEAL Delivery Vehicle (SDV) performance in cold water. 2.6 Exercise and Mission-Related Physiology 2.6.1 Health surveillance for SOF personnel. 2.6.2 Pain suppression modalities in Special Operations. 2.6.3 Human performance enhancements; evaluation of alertness enhancing agents. 3. It is not the intent of this solicitation to fund the FDA approval of devices or drugs, although cooperative research and development that promotes or accelerates FDA approval of such items if they were of high value to SOF would be considered. Furthermore, it is not the intent of this solicitation to establish new facilities, rather, institutions having demonstrated research capability and the necessary facilities are invited to submit a project pre-proposal not exceeding three pages of text that describes: 3.1 The research objective, 3.2 The research approach, 3.3 Related work by the proposer, 3.4 Anticipated contributions to the USSOCOM program, and 3.5 An estimate of overall costs (including indirect) for up to a three year effort. 3.6 A curriculum vitae of the principal investigator(s) should be appended together with any supporting information, such as reprints or preprints, that will assist in the evaluation of the pre-proposal. 4. Evaluation Criteria. Pre-proposals, and any follow-up full proposal submission, will be evaluated on the following criteria: 4.1 Scientific and technical merits of the research. 4.2 Qualifications and experience of the principal investigator(s), and availability of facilities to support the research. 4.3 Relevance of the proposed research to USSOCOM program priorities. 4.4 Realism of proposed costs, and availability of funds. 5. Award. Based upon the criteria identified above USSOCOM will award single or multiple contracts in accordance with technical priority and funding availability. 6. There will be no other requests for proposals or other formal solicitations regarding this announcement. Formal full proposals for competitive review will be requested based on those pre-proposal submissions judged most likely to meet program objectives. Proposal deadline date and format instruction will be provided at that time. This solicitation is open to pre-proposals beginning 1 May 2001. Pre-proposals may be submitted after that date and until 30 April 2003 for consideration in subsequent funding cycles. Pre-proposals should be sent to: US Special Operations Command ATTN: SOAL-T (David Saren-Program Manager Special Operations Medical Technology Development Program) 7701 Tampa Point Boulevard MacDill AFB, FL, 33621-5323 Or by e-mail to: Mr. Saren at sarend@socom.mil. Any additional questions relating to this BAA should be directed to: US Special Operations Command ATTN: SOAL-KB (Mr. John S. Thompson), 7701 Tampa Point Blvd, MacDill AFB, FL 33621-5323, or via e-mail at thompsj@socom.mil, or telephonically (813) 828-7077. **************************

Record

Loren Data Corp. 20010522/ASOL003.HTM (W-138 SN50M4T5)